DPI-386 Nasal Gel

DRUG6 trials

Sponsors

Repurposed Therapeutics, Inc.

Conditions

Motion SicknessMotion Sickness, SpaceMotion SimulationParabolic FlightSea Sickness

Phase 2

DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness

TerminatedNCT04219982

Repurposed Therapeutics, Inc.Motion Sickness

Start: 2018-06-29End: 2019-01-28Updated: 2020-01-07

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

RecruitingNCT05852730

Repurposed Therapeutics, Inc.Motion Sickness, Space, Motion Simulation, Parabolic Flight

Start: 2021-08-10End: 2026-09-30Target: 80Updated: 2024-05-16

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

RecruitingNCT05886660

Repurposed Therapeutics, Inc.Motion Sickness, Motion Sickness, Space, Sea Sickness

Start: 2022-01-21End: 2024-09-30Target: 30Updated: 2024-05-17

Phase 3

Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness

CompletedNCT04184115

Repurposed Therapeutics, Inc.Motion Sickness

Start: 2019-06-09End: 2019-06-11Updated: 2019-12-03

Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

CompletedNCT04947423

Repurposed Therapeutics, Inc.Motion Sickness

Start: 2021-06-14End: 2021-08-12Updated: 2021-09-17

Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

CompletedNCT05548270

Repurposed Therapeutics, Inc.Motion Sickness

Start: 2022-08-23End: 2022-11-29Updated: 2023-03-21